The great advantage of a brownfields project, within the shadow of a previous mine’s headframe, is you are almost certain to find gold. But is that enough?
At the request of IIROC, the Company wishes to retract and clarify certain disclosure in its January 15, 2019 news release. Specifically, the disclosure “doubling resource potential” is a violation of NI 43-101, 2.3(1)(a) – Restricted Disclosure, as “resource potential” is not a recognized term for Canadian securities legislation, nor can “resource potential” be “doubled” and is therefore misleading. All references to “resource potential” and “doubling resource potential” are retracted. The drill results disclosed in the news release should have been disclosed as exploration results and are accordingly clarified in this release.
FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) would like to congratulate Cannara Biotech Inc. (“Cannara”) for its listing approval and commencement of trading on the Canadian Securities Exchange (“CSE”) today under the stock symbol “LOVE”. FSD Pharma, directly or indirectly, acquired ownership of 85,003,750 common shares (“Common Shares”) of the Issuer, representing 12.25% of the issued and outstanding Common Shares of the Issuer.
FSD Pharma (“FSD“) announced today that, in connection with the business combination (the “Business Combination“) completed on December 31, 2018 among Cannara Biotech Inc. (formerly, Dunbar Capital Corp.) (the “Issuer“), Cannara Biotech Inc. and 11038427 Canada Inc., FSD Pharma, directly or indirectly, acquired ownership of 85,003,750 common shares (“Common Shares“) of the Issuer, representing 12.25% of the issued and outstanding Common Shares of the Issuer.